AU4303500A - Use of (2s)-1- ((2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1(h)- indole-2-carbonyl) pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon - Google Patents

Use of (2s)-1- ((2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1(h)- indole-2-carbonyl) pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon

Info

Publication number
AU4303500A
AU4303500A AU43035/00A AU4303500A AU4303500A AU 4303500 A AU4303500 A AU 4303500A AU 43035/00 A AU43035/00 A AU 43035/00A AU 4303500 A AU4303500 A AU 4303500A AU 4303500 A AU4303500 A AU 4303500A
Authority
AU
Australia
Prior art keywords
dimethoxybenzenesulfonyl
carboxamide
pyrrolidine
indole
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43035/00A
Inventor
Remi Brouard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU4303500A publication Critical patent/AU4303500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
AU43035/00A 1999-04-29 2000-04-25 Use of (2s)-1- ((2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1(h)- indole-2-carbonyl) pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon Abandoned AU4303500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905434 1999-04-29
FR9905434A FR2792834A1 (en) 1999-04-29 1999-04-29 USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON
PCT/FR2000/001085 WO2000066117A1 (en) 1999-04-29 2000-04-25 Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon

Publications (1)

Publication Number Publication Date
AU4303500A true AU4303500A (en) 2000-11-17

Family

ID=9545016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43035/00A Abandoned AU4303500A (en) 1999-04-29 2000-04-25 Use of (2s)-1- ((2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1(h)- indole-2-carbonyl) pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon

Country Status (4)

Country Link
AR (1) AR023617A1 (en)
AU (1) AU4303500A (en)
FR (1) FR2792834A1 (en)
WO (1) WO2000066117A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2679903B1 (en) * 1991-08-02 1993-12-03 Elf Sanofi DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2714378B1 (en) * 1993-12-24 1996-03-15 Sanofi Sa Indol-2-one derivatives substituted in 3 with a nitrogen group, their preparation, pharmaceutical compositions containing them.
FR2775598A1 (en) * 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS

Also Published As

Publication number Publication date
FR2792834A1 (en) 2000-11-03
WO2000066117A1 (en) 2000-11-09
AR023617A1 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
AUPQ544900A0 (en) Treatment of cellulosic material
AU2002223081A1 (en) Personal care compositions
HUP0400636A3 (en) Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and preparation thereof
AU4067800A (en) Surgical bone screw
IL148470A0 (en) Electrosurgical coagulating and cutting instrument
AU6779900A (en) Discontinuous films from skin care compositions
AU2224300A (en) Portable oral irrigator
DE50002713D1 (en) MEDICAL BIPOLAR TISSUE CUTTING INSTRUMENT
AU2001273132A1 (en) Compounds to treat alzheimer's disease
TWI315989B (en) Soy depigmenting and skin care compositions
AU2003299848A1 (en) Intraoral calculus dissolving gel composition
AU3573399A (en) Skin whitening composition
AU2002258559A1 (en) Skin care compositions
AU2003284225A8 (en) Skin care composition containing an anionic polymer
AU2001293372A1 (en) Substituted 1,4-thiazepine and analogs and their use as activators of caspases
AU2001265253A1 (en) Treatment of hiv using hyperthermia
IT1302264B1 (en) DERIVATIVES WITH N-ACYL VANILLYAMIDE STRUCTURE ABLE TO ACTIVATE PERIPHERAL IRECEPTORS OF CANNABINOIDS
AU4647200A (en) Skin care compositions containing combination of skin care actives
AU2000236008A1 (en) Treatment for dry mouth employing carbamide peroxide
AU4361600A (en) Skin care compositions containing combination of skin care actives
AU4647300A (en) Skin care compositions containing combination of skin care actives
AU5416000A (en) Sulfonamide substituted benzylamine derivatives and their use as medicaments
AU4303500A (en) Use of (2s)-1- ((2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1(h)- indole-2-carbonyl) pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon
WO2001043705A3 (en) Compositions containing a retinoid and a stilbene for skin care
NO20005259L (en) Process for the preparation of enantiomerically pure N-methyl-N - [(1S) -1-phenyl-2 - ((3S) -3-hydroxypyrrolidin-1-yl) ethyl] -2,2-diphenylacetamide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase